Subscribe To
Palisade Bio Reports Second Quarter 2023 Financial Results
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today summarized […] The post Palisade Bio Reports Second Quarter 2023 Fin...
Read More
Posted: Aug 11 2023, 12:05
Author Name: forextv
Views: 022252